N/A
Completed N=11
Study Evaluating Liver Transplantation in Haemophilia Patients in Spain
Hemophilia · Hemophilia B
Source: ClinicalTrials.gov NCT00927992 ↗
Enrolled (actual)
11
Serious AEs
—
Results posted
Jan 2013
Primary outcomePrimary: Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation — 7; 6; 4; 3 Participants
Summary
This study will analyze survival and outcome of patients with severe haemophilia who undergo liver transplantation in Spain
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation |
7; 6; 4; 3; 1 | — |
| PRIMARY Number of Participants With Acute Rejection of Liver Transplant |
— | — |
| PRIMARY Number of Participants With Hepatitis C Viral Infection Recurrence After Liver Transplantation |
4 | — |
| PRIMARY Number of Participants Who Survived After Liver Transplantation |
10 | — |
| SECONDARY Number of Participants Requiring Exogenous Clotting Factor Infusion During Liver Transplantation |
5; 3 | — |
| SECONDARY Dose of Exogenous Clotting Factors Used During Liver Transplantation |
62.88 | — |
| SECONDARY Number of Participants With and Without Hemophilia Requiring Immunosuppressive Therapy, Had Acute Rejection, Hepatitis C Viral Infection Recurrence and Who Survived After Liver Transplantation |
— | — |
Eligibility Criteria
Inclusion Criteria
- Patients with haemophilia who underwent liver transplantation and who have been followed-up at any site in Spain.
Exclusion Criteria
- Patients without informed consent form.
Data sourced from ClinicalTrials.gov (NCT00927992). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.